PMC:7463108 / 84814-85098 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T818","span":{"begin":34,"end":37},"obj":"Body_part"},{"id":"T819","span":{"begin":57,"end":61},"obj":"Body_part"},{"id":"T820","span":{"begin":121,"end":125},"obj":"Body_part"}],"attributes":[{"id":"A818","pred":"fma_id","subj":"T818","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A819","pred":"fma_id","subj":"T819","obj":"http://purl.org/sig/ont/fma/fma54541"},{"id":"A820","pred":"fma_id","subj":"T820","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Fig. 5 Differential inhibition of HIV-1 entry into human glia by maraviroc and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions in combination with morphine. (a) Construction of a MOR-CCR5 heterodimer model in a membrane (gray), and aqueous surrounds (red) system."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T876","span":{"begin":51,"end":56},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T877","span":{"begin":79,"end":80},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T878","span":{"begin":121,"end":125},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T879","span":{"begin":179,"end":180},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T880","span":{"begin":198,"end":199},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T881","span":{"begin":230,"end":231},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T882","span":{"begin":232,"end":240},"obj":"http://purl.obolibrary.org/obo/UBERON_0000158"}],"text":"Fig. 5 Differential inhibition of HIV-1 entry into human glia by maraviroc and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions in combination with morphine. (a) Construction of a MOR-CCR5 heterodimer model in a membrane (gray), and aqueous surrounds (red) system."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5718","span":{"begin":65,"end":74},"obj":"Chemical"},{"id":"T295","span":{"begin":99,"end":109},"obj":"Chemical"},{"id":"T15052","span":{"begin":168,"end":176},"obj":"Chemical"}],"attributes":[{"id":"A50134","pred":"chebi_id","subj":"T5718","obj":"http://purl.obolibrary.org/obo/CHEBI_63608"},{"id":"A7796","pred":"chebi_id","subj":"T295","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A21896","pred":"chebi_id","subj":"T15052","obj":"http://purl.obolibrary.org/obo/CHEBI_17303"},{"id":"A56582","pred":"chebi_id","subj":"T15052","obj":"http://purl.obolibrary.org/obo/CHEBI_58097"}],"text":"Fig. 5 Differential inhibition of HIV-1 entry into human glia by maraviroc and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions in combination with morphine. (a) Construction of a MOR-CCR5 heterodimer model in a membrane (gray), and aqueous surrounds (red) system."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2881","span":{"begin":90,"end":94},"obj":"Gene"},{"id":"2882","span":{"begin":95,"end":98},"obj":"Gene"},{"id":"2883","span":{"begin":200,"end":203},"obj":"Gene"},{"id":"2884","span":{"begin":204,"end":208},"obj":"Gene"},{"id":"2894","span":{"begin":34,"end":39},"obj":"Species"},{"id":"2895","span":{"begin":51,"end":56},"obj":"Species"},{"id":"2900","span":{"begin":168,"end":176},"obj":"Chemical"}],"attributes":[{"id":"A2881","pred":"tao:has_database_id","subj":"2881","obj":"Gene:1234"},{"id":"A2882","pred":"tao:has_database_id","subj":"2882","obj":"Gene:4988"},{"id":"A2883","pred":"tao:has_database_id","subj":"2883","obj":"Gene:4988"},{"id":"A2884","pred":"tao:has_database_id","subj":"2884","obj":"Gene:1234"},{"id":"A2894","pred":"tao:has_database_id","subj":"2894","obj":"Tax:11676"},{"id":"A2895","pred":"tao:has_database_id","subj":"2895","obj":"Tax:9606"},{"id":"A2900","pred":"tao:has_database_id","subj":"2900","obj":"MESH:D009020"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Fig. 5 Differential inhibition of HIV-1 entry into human glia by maraviroc and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions in combination with morphine. (a) Construction of a MOR-CCR5 heterodimer model in a membrane (gray), and aqueous surrounds (red) system."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1139","span":{"begin":0,"end":284},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fig. 5 Differential inhibition of HIV-1 entry into human glia by maraviroc and a bivalent CCR5-MOR antagonist (BVL) with cell-specific interactions in combination with morphine. (a) Construction of a MOR-CCR5 heterodimer model in a membrane (gray), and aqueous surrounds (red) system."}